Evidence map›Paper›PMID 26773011›Full record

ReviewAdvances in nutrition (Bethesda, Md.)2016

Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes.

Jill L Sherriff, Therese A O'Sullivan, Catherine Properzi, Josephine-Lee Oddo, Leon A Adams

Open access · bronzeAbstract readReview
In one paragraph

Review in Advances in nutrition (Bethesda, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 1 synthesis or guideline pooled it, 189 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol-Related Liver Disease: A Cross-Sectional Metabolomics Study.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  14. Article
  15. Article
  16. Foods (Basel, Switzerland) · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jill L SherriffSchool of Public Health, Curtin Health Innovation Research Institute-Metabolic Health, Curtin University, Bentley, Australia; J.Sherriff@curtin.edu.au.
Therese A O'SullivanSchool of Exercise and Health Science, Edith Cowan University, Joondalup, Australia;
Catherine ProperziSchool of Exercise and Health Science, Edith Cowan University, Joondalup, Australia;
Josephine-Lee OddoSchool of Exercise and Health Science, Edith Cowan University, Joondalup, Australia;
Leon A AdamsSchool of Medicine and Pharmacology, The University of Western Australia, Nedlands, Australia; and Liver Transplant Unit, Sir Charles Gairdner Hospital, Nedlands, Australia.
Edith Cowan University · AUCurtin University · AUSir Charles Gairdner Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our understanding of the impact of poor hepatic choline/phosphatidylcholine availability in promoting the steatosis characteristic of human nonalcoholic fatty liver disease (NAFLD) has recently advanced and possibly relates to phosphatidylcholine/phosphatidylethanolamine concentrations in various, membranes as well as cholesterol dysregulation. A role for choline/phosphatidylcholine availability in the progression of NAFLD to liver injury and serious hepatic consequences in some individuals requires further elucidation. There are many reasons for poor choline/phosphatidylcholine availability in the liver, including low intake, estrogen status, and genetic polymorphisms affecting, in particular, the pathway for hepatic de novo phosphatidylcholine synthesis. In addition to free choline, phosphatidylcholine has been identified as a substrate for trimethylamine production by certain intestinal bacteria, thereby reducing host choline bioavailability and providing an additional link to the increased risk of cardiovascular disease faced by those with NAFLD. Thus human choline requirements are highly individualized and biomarkers of choline status derived from metabolomics studies are required to predict those at risk of NAFLD induced by choline deficiency and to provide a basis for human intervention trials.

Indexed as

BacteriaCholineDeficiency DiseasesHumansLiverNon-alcoholic Fatty Liver DiseasePhosphatidylcholinesPhosphatidylethanolaminesPolymorphism, GeneticCholinePhosphatidylcholinesphosphatidylethanolaminePhosphatidylethanolaminescholineliver diseasesmicrobiomeNAFLDnonalcoholic steatosisphosphatidylcholine

Identifiers

PMID26773011
PMCPMC4717871
OpenAlexW2296386264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.